Compounds / Chonluten
Chonluten
Also known as: EDG (Glu-Asp-Gly) short peptide bioregulator; tripeptide T-34; CAS 75007-24-8; ChEBI CHEBI:162780
Primary research focus: Bronchopulmonary and respiratory-tissue research (Khavinson short-peptide bioregulator)
Last updated July 2026 · Reviewed against FDA labeling and published research.
What is Chonluten?
Chonluten is a short synthetic peptide bioregulator from the Khavinson family, the tripeptide Glu-Asp-Gly (EDG), also designated T-34. It was developed at the St. Petersburg Institute of Bioregulation and Gerontology and is studied preclinically for effects on bronchial and pulmonary epithelium (with secondary interest in gastric mucosa). It is a research compound with no FDA approval and no completed Western clinical trials.
Khavinson short peptides are proposed to enter cells and the nucleus and bind specific DNA and chromatin regions, modulating tissue-specific gene expression rather than acting on cell-surface receptors. For Chonluten, preclinical work reports modulation of respiratory-epithelial gene programs and stress-response and inflammatory signaling (for example ERK1/2 and JNK pathways, and genes such as HSP70, SOD, and COX-2). This epigenetic/DNA-binding mechanism is class-level and not independently well-replicated; treat it as proposed rather than established.
How it’s supplied
Not an FDA-approved or commercially manufactured medicine. It is sold as a research-grade lyophilized powder (for example, 20 mg vials) for reconstitution. Research-grade products are not FDA-reviewed for potency or sterility.
Dosage Chart
Units shown are for a U-100 insulin syringe (100 units = 1 mL), calculated from the vial size and BAC water you select. Always confirm against your prescription and your syringe markings.
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Weeks 1-2 | 0.25mcg | 1x Daily | — |
| Weeks 3-4 | 0.50mcg | 1x Daily | — |
| Weeks 5-6 | 1mg | 1x Daily | — |
| Weeks 7-8 | 1.5mg | 1x Daily | — |
| Weeks 9-10 | 2mg | 1x Daily | — |
| Weeks 11-12 | 3mg | 1x Daily | — |
| Weeks 13-16 | 4mg | 1x Daily | — |
- Rotate injection sites to reduce irritation and lipohypertrophy
- Not for use during pregnancy or breastfeeding
- Do not exceed the recommended dose to try to speed results
Potential Benefits and Side Effects
Effects reported in published research. Not a promise of results, and not medical advice.
- Reported in preclinical (cell and animal) research within the Khavinson tradition; not established in Western clinical trials.
- Modulation of respiratory-epithelial gene expression toward normal patterns in models.
- Reported anti-inflammatory and stress-protective effects in bronchopulmonary and monocyte/macrophage models.
- Proposed support of bronchial epithelial integrity under stress conditions.
- No human adverse-effect data are available.
- The Khavinson short-peptide class is reported to have a clean safety profile in Russian use, but this is not established by Western trials for Chonluten specifically.
- Human tolerability is unknown.
Warnings and contraindications
Important safety information. This is not exhaustive — read the full prescribing information and consult your prescriber or pharmacist.
- No FDA-approved labeling exists; the following reflect the compound's status and the limits of its evidence, not established label warnings.
- There are no completed Western human clinical trials of Chonluten; its human safety profile is not established.
- The proposed DNA-binding mechanism is class-level and not independently well-replicated.
- Research-grade material varies in identity and purity.
- Safety in pregnancy and breastfeeding has not been studied.
- Not established; no FDA-approved labeling. Precautionary considerations include known hypersensitivity to the peptide.
Reconstitution Steps
How to prepare the lyophilized vial. Confirm specifics with your pharmacist or prescriber.
- Confirm the amount of peptide in the vial and the volume of diluent you intend to use before starting.
- Wash your hands and gather supplies: the lyophilized vial, the diluent (typically bacteriostatic water), an alcohol swab, and a sterile syringe.
- Let the vial and diluent reach room temperature if they were refrigerated or frozen.
- Wipe the rubber stopper of both the peptide vial and the diluent vial with a fresh alcohol swab and let them air dry.
- Draw the intended diluent volume into the syringe.
- Insert the needle into the vial and slowly release the diluent down the inside wall rather than directly onto the powder, to avoid foaming.
- Do not shake. Gently swirl or roll the vial until fully dissolved.
- Inspect the solution: it should be clear and colorless with no visible particles. Do not use if cloudy or containing particles.
- Note the resulting concentration (amount divided by diluent volume) so it matches the reconstitution calculator on this page.
- Label the vial with the reconstitution date and store as directed under reconstituted storage.
US regulatory status
Classifications are public record but can change. For reference only, not legal advice.
Development: Chonluten is part of the Khavinson short-peptide bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology, studied since the 1970s and reported largely in Russian-language literature. It is the bronchial/respiratory member of the class. Compound-specific published evidence is limited and preclinical (in vitro and animal), and independent Western replication of both mechanism and outcomes is sparse. A 2020 Khavinson-group review discussed it in the context of respiratory pathology. There is no FDA approval, no public IND, and no registered Western clinical trial.
Notes: Chonluten is not FDA-approved and has no recognized clinical use in the US. It is not on the FDA 503A bulk drug substances list and has no approval or shortage basis for compounding, so it is not eligible for 503A or 503B compounding. It is sold as a research-grade chemical; such products are not FDA-reviewed for safety, potency, or sterility. It is not a controlled substance.
International status
Pharmacokinetics
Storage and handling
Important Notes
Practical considerations for consistency and safety.
- Chonluten (Glu-Asp-Gly) is the bronchial/respiratory member of the Khavinson bioregulator family; it shares the Glu-Asp core with Crystagen but differs in the third residue.
- The evidence base is preclinical and largely Russian; the proposed epigenetic mechanism is class-level and not independently well-replicated.
- It is a research compound, not an FDA-approved drug, and research-grade material varies in purity.
Lifestyle Factors
- Khavinson bioregulators are typically studied in short cyclic courses rather than continuous daily use.
- Human lifestyle interactions are unstudied for Chonluten.
References
Related compounds
Important disclaimer
This page is an educational reference, not medical advice, a diagnosis, or a treatment recommendation, and not a substitute for your prescriber or pharmacist. Approval and regulatory status varies by compound and can change. Always confirm against current prescribing information and consult a qualified healthcare professional before making any decision about a medication.